Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

Stryker Corporation SYK, one of the largest medical device companies in the global orthopedic market, has successfully expanded its product portfolio over time that aids the company to cater to evolving demands of customers.

Markedly, the company boasts a diverse portfolio that has been aiding top-line growth, reflected through projected revenue growth of 8.53%. We expect the momentum to continue, banking on the strength of its portfolio and acquisitions.

In fact, the company’s product portfolio cushions it against any significant sales shortfall during economic downturns. The Kalamazoo, MI-based company's pipeline include products for Hip, Knee and Mako Robotic-Arm Assisted Surgeries. MAKO results in the last quarter were solid, with almost 26 global robot installations, of which, 24 were in the United States.

Furthermore, the platforms of bone cement, sports-medicine, bones substitute, soft tissue repair, trauma and extremities, endoscopy and more fortify the company’s market position. Meanwhile, Stryker’s exclusive navigation platform provides streamlined software solutions that allow surgeons to accurately track, analyze and monitor instrumentation pertaining to a patient’s anatomy during surgical procedures to enhance patient outcomes. We expect Stryker to perform well by virtue of its strong and diverse portfolio, innovative pipeline, strategic acquisitions along with ongoing cost control measures and increasing operating efficiency.

Stryker has been following an acquisition-driven strategy to boost growth profile. The acquisition of NOVADAQ Technologies Inc completed in September is a recent example.

Also, Stryker has been focusing on international growth as well. In particular, the company’s Medsurg product line has witnessed strong demand in the European and Australian markets in 2017. However, China might prove to be a challenging market.

On the flip side, Stryker along with its peers like Orthofix International N.V. OFIX, Female Health Company VERU and LeMaitre Vascular, Inc LMAT continues to be challenged by lower demand for health care products. Additionally, the company’s spine business in the United States witnessed supply issues in 2017. It has been facing challenging global economic conditions, particularly in the United States and Western Europe as well. Going forward, lower reimbursements for medical products and services may impose a downward pressure on the prices for the company’s products, which are expected to have an impact on the top line.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Stryker Corporation (SYK) : Free Stock Analysis Report
 
Orthofix International N.V. (OFIX) : Free Stock Analysis Report
 
LeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report
 
Female Health Company (The) (VERU) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research